



PATENT #

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Claiborne, et al.

Group Art No.: 1625

Serial No.: 09/997,323

Examiner: Desai, R.

Filed: November 30, 2001

Title: FARNESYLTRANSFERASE
INHIBITORS

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:
Assistant Commissioner for Patents
Washington, D.C. 20231, on:

Case No.: 6754.US.02

Date of Deposit: November 7, 2002

Tanya M. Parent 11/7/02
Tanya M. Parent Date

RECEIVED
NOV 15 2002
TECH CENTER
6500/2900Commissioner for Patents
Washington, D.C. 20231INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in 37 C.F.R. § 1.97(b) but to the undersigned's knowledge, before the mailing date of either a Final Action or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a statement as specified by 37 C.F.R. § 1.97(e). Applicant respectfully petitions and requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

Documents listed in this Information Disclosure Statement were first cited in a communication from a Foreign Patent Office by the European Patent Office, in a counterpart international PCT application. This Information Disclosure Statement is being filed within three month of the mailing date of that communication. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered. A duplicate of this sheet is enclosed.



23492

ABBOTT LABORATORIES
Telephone: (847) 937-0042
Facsimile: (847) 938-2623Respectfully submitted,
Claiborne, et al

Gregory W. Steele
Gregory W. Steele
Registration No. 33,796
Attorney for Applicants